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Statement of Translational Relevance 
Allogeneic hematopoetic stem-cell transplantation (HSCT) remains the most 
effective form of cellular immunotherapy for patients with acute myeloid leukemia 
and myelodysplasia but the lack of fully-matched donors currently limits applicability 
of this treatment. The use of more widely available haploidentical (half-matched) 
donors has been associated with delayed immune reconstitution and increased graft-
versus-host disease (GvHD). We previously used the approach of alloanergization of 
T-cells within donor bone marrow to facilitate haploidentical HSCT.   We now show in 
a novel Phase 1 study that infusion of low doses of alloanergized donor lymphocyte 
infusions (aDLI) after CD34-selected myeloablative haploidentical HSCT is feasible 
at multiple clinical sites and improves immune reconstitution without excess GvHD. 
Importantly we also show administration of aDLI expands frequencies of potentially 
tolerogenic regulatory T cells in vivo, a mechanism which could further improve post-




Purpose: Allogeneic hematopoietic stem-cell transplantation (HSCT) is a curative 
treatment for many hematologic cancers. Use of haploidentical (mismatched) donors 
increases HSCT availability but is limited by severe graft-versus-host disease 
(GvHD) and delayed immune reconstitution. Alloanergization of donor T-cells is a 
simple approach to rebuild immunity whilst limiting GvHD after haploidentical HSCT 
but the optimal T-cell dose and impact on immune reconstitution remain unknown.   
Experimental Design: We performed a multicentre Phase 1 trial of alloanergized 
donor lymphocyte infusion (aDLI) after CD34-selected myeloablative haploidentical 
HSCT. The primary aim was feasibility and safety with secondary aims of assessing 
the less frequently addressed issue of impact on immune reconstitution. 
Results: Nineteen high-risk acute leukemia or myelodysplasia patients were 
enrolled. Engraftment occurred in 18/19 patients (95%). Pre-aDLI, twelve patients 
(63%) had bacteremia, 9/17 at-risk patients (53%) reactivated CMV and one 
developed acute GvHD. Sixteen patients received aDLI at dose-levels 1 (103 T-
cells/kg, n=4), 2 (104, n=8), and 3 (105, n=4). Post-aDLI, 5 patients developed 
clinically significant acute GvHD and 4/14 at-risk patients (29%) reactivated CMV. T-
cell recovery was significantly greater and functional virus- and tumor-associated 
antigen-specific T-cells were detectable earlier in patients receiving dose-level 2 or 3 
vs dose-level 1/no aDLI. Alloanergization of donor cells expanded the CD4+ T-
regulatory cell frequency within aDLI which increased further in vivo without 
impeding expansion of virus- and tumor-associated antigen-specific T-cells. 
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Conclusion: These data demonstrate safety and a potential role for aDLI in 
contributing to immune reconstitution and expanding tolerogenic regulatory T-cells in 




Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative 
therapy for many patients with high-risk hematologic malignancies, but not all will 
have fully human leucocyte antigen (HLA)-matched donors. In contrast, most 
patients will have haploidentical family donors, the use of which would significantly 
increase availability of HSCT as a treatment modality.1 Historically, haploidentical 
HSCT has resulted in increased frequency and severity of acute graft-versus-host 
disease (aGvHD),2,3 mediated by alloreactive donor T-cells.4 Various methodologies 
to deplete donor T-cells have significantly reduced incidences of severe aGvHD after 
haploidentical HSCT.5,6 However, these non-selective T-cell depletion (TCD) 
strategies also remove pathogen- and tumor-antigen-reactive T-cells, which 
contributes to delayed immune reconstitution, and increased infection and disease 
relapse rates.7-9  
Several approaches have therefore been developed to selectively deplete T-cells 
most likely to mediate GvHD from haploidentical donors, including depletion of α/β T-
cells,10 or selective removal of alloreactive T-cells.11,12 Although some of these 
strategies have been shown to be feasible in early clinical studies,13,14 they are 
technically complex and may also deplete desirable effector and CD4+ regulatory T-
cells (Treg) from the donor pool.  More recently, post-transplant cyclophosphamide 
(PTC) after haploidentical HSCT has been successfully adopted to inhibit 
proliferation of alloreactive donor T-cells in vivo.15 Although early reports suggest this 
approach results in less viral reactivation and infection than non-selective TCD 
strategies,16 infections common to immunocompromised populations continue to be 
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reported and the degree and temporal sequence of broad immune reconstitution 
after PTC-haploidentical HSCT have yet to be determined. 
An unmet need therefore remains for strategies that facilitate haploidentical 
transplantation without negatively impacting beneficial immune reconstitution. One 
such approach is alloanergization, the induction of alloantigen-specific 
hyporesponsiveness in donor T-cells by recipient alloantigen presentation with 
concurrent co-stimulatory blockade.17 This strategy was successfully employed in 2 
prior clinical studies in which very large doses of haploidentical alloanergized donor 
T-cells were infused en mass with donor bone marrow (BM), resulting in less severe 
aGvHD than historical control recipients of non-TCD haploidentical BM 
transplantation (BMT).18,19 Furthermore, the approach does not require the 
generation of specialized recipient antigen-presenting cells or sorting technologies, 
retains the majority of pathogen-and tumor-antigen specific T-cells in vitro,19 and 
results in expansion of allospecific donor Tregs in vivo which may in turn contribute 
to the control of harmful alloresponses.20  
However, the previous studies of alloanergized BMT were not designed to determine 
the impact of alloanergized donor T-cells on immune reconstitution or to define the 
minimal or optimal dose of alloanergized donor T-cells able to confer clinically 
beneficial virus-specific immunity whist maintaining an acceptable toxicity profile. To 
address these issues, we therefore conducted a novel multicenter Phase 1 clinical 
study examining toxicity and immune reconstitution after administration of escalating 
doses of alloanergized donor lymphocyte infusion (aDLI) in patients with high-risk 
acute leukemia or myelodysplasia after CD34+-selected (i.e. non-selectively T-cell 
depleted) myeloablative HSCT from haploidentical related donors.  
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Materials and methods 
Study design and eligibility 
This was an open-label phase I trial to establish the feasibility and safety of delayed 
administration of aDLI after CD34+-selected myeloablative haploidentical HSCT in 
patients with hematopoietic malignancies. The primary aim of the study was to 
assess feasibility and safety of this strategy during two consecutive study stages 
defined for each patient.  The first comprised the period prior to aDLI infusion during 
which the toxicity of the conditioning regimen, the likelihood of engraftment and the 
subsequent percentage of individuals who would be eligible to receive aDLI were 
determined.  The second comprised the period from aDLI infusion through D+100 
(as the at-risk period for aGVHD).   Preliminary efficacy was addressed in the 
secondary aim with determination of immune reconstitution and viral infection rates 
in patients receiving aDLI.  Adult and pediatric patients with high-risk hematological 
malignancies (acute leukemia in first remission with high-risk cytogenetics or second 
or subsequent remission, high-risk myelodysplasia or acute myelogenous leukemia 
with induction failure after at most 2 regimens) without either available genotypically 
HLA-matched (6/6) unrelated donors (after a search of longer than 2 months or with 
high-risk of progression during a search) or fully-matched/single HLA-antigen-
mismatched related donors, but with available haploidentical related donors were 
eligible for inclusion at 5 US centers (Supplementary Methods).  The study was 
conducted in accordance with the Belmont Report and all patients and/or legal 
guardians gave consent and/or assent as age-appropriate. The study was approved 
by local institutional review boards and by the US Food and Drug Administration and 
registered at ClinicalTrials.gov (Identifier: NCT00475384). 
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Patient characteristics and treatment regimens 
Nineteen patients received either total body irradiation (TBI)-based (n=8) or 
chemotherapy-based (n=11) myeloablative conditioning at the site investigator’s 
discretion.  After conditioning, patients received CliniMACS-selected CD34+ G-CSF-
mobilized peripheral blood cells from haploidentical related donors (median age 39 
years, range 19- 50) at D0. Patient and donor characteristics and conditioning 
regimens are shown in Table S1. Of the 10 male and 9 female patients, five were 
children (median age 7 years, range 2-17) of whom 3 were white/non-Latino and 2 
white/Latino; fourteen were adults (median age 39 years, range 22-50) of whom 6 
were white/non-Latino, 3 black non-Latino and 5 white/Latino. No post-transplant 
immune suppression was used. Neutrophil engraftment was defined as the first of 
three consecutive days on which the patient’s absolute neutrophil count was > 
500/µL. Chimerism was assessed by D+28 on unselected and CD3+ fractions of 
peripheral blood using DNA polymerase chain reaction (PCR) of short tandem 
repeats. Supportive care included antibacterial, antifungal and PCP prophylaxis per 
institutional practice. For recipients at risk of CMV reactivation (donor and/or 
recipient CMV IgG-seropositive) systemic anti-CMV prophylaxis was recommended 
from the initiation of conditioning through D+75 unless contraindicated and thereafter 
at the discretion of the treating physician.  Physicians were encouraged to use a 
strategy of CMV-DNA monitoring and pre-emptive therapy upon reactivation for all 
at-risk patients. 
Generation of alloanergized donor lymphocyte infusions 
ADLI were generated ex vivo under Good Manufacturing Practice conditions by co-
culture of fresh non-mobilized peripheral blood mononuclear cells (PBMC) from the 
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stem cell donor with gamma-irradiated allostimulator PBMC. In order to both ensure 
adequate numbers of allostimulator cells were available, and reduce theoretical 
concerns regarding possible anergization to tumor-associated antigens present in 
the patient, where the patient had a suitable second haploidentical family member 
sharing the haplotype possessed by the patient but not by the stem cell/aDLI donor, 
fresh, non-mobilized PBMC obtained from the second haploidentical family member 
were used as allostimulators. Where the patient lacked such a suitable second 
haploidentical family member, non-mobilized patient PBMC were obtained prior to 
transplant and cryopreserved for later thaw and use as allostimulators. Non-
mobilized PBMC from stem cell/aDLI donors were obtained on D+32/39 and 
alloanergized by co-culture with equal numbers of irradiated (33 Gy) allostimulators 
in the presence of humanized anti-B7.1/2 antibodies as described (clones h1F1 and 
h3D1, Wyeth, Madison, NJ).19 Control flasks with donor PBMC and irradiated 
allostimulators without anti-B7 antibodies were set up in parallel. After 72 hours, 
alloanergized donor lymphocytes were harvested, washed twice and sampled for 
viability, contamination (Gram stain, Mycoplasma testing, bacterial and fungal 
cultures), endotoxin levels, and flow cytometric phenotype (see Supplementary 
Methods). Residual alloreactivity was determined by measuring residual proliferative 
stimulator-specific alloresponses in secondary mixed lymphocyte reactions, as 
previously described and calculated as 
Residual alloreactivity (%) = 100*counts per minute (cpm) in alloanergized PBMC/ 
cpm in allostimulated PBMC.  
ADLI were infused fresh, prior to phenotypic assessment and determination of 
residual alloreactivity, if they met release criteria (sufficient T-cell numbers with 
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>/=70% viability, no evidence of bacterial contamination and endotoxin levels </= 5 
EU/kg/). A schema for the study is shown in Figure S1. 
Dosing and administration of aDLI 
Patients who were stably engrafted with no active aGVHD or uncontrolled infection 
received aDLI on D+35. Patients who did not fulfil these criteria could be delayed for 
one week and reassessed. Twelve patients received aDLI on D+35 as scheduled, 
while 4 received their aDLI after a one week delay (3 due to viral reactivation and 
one due to active aGVHD). A Bayesian, adaptive study design based on efficacy and 
toxicity seen in prior patients was used to assign the aDLI dose for each patient.21 
For this purpose, efficacy was defined as stable engraftment (absolute neutrophil 
count > 500/µL by D+100) and toxicity was defined as severe refractory aGVHD (see 
below) or a grade 4 adverse event (graded per The Common Terminology Criteria 
for Adverse Events (CTCAE v.3) between the time of aDLI and D+100 that was 
possibly, probably or definitely related to the aDLI. The aDLI consisted of PBMC with 
the total cell number adjusted to contain the indicated dose of CD3+ T-cells/kg. The 
initial starting aDLI dose for the first patient was 103 CD3+ T-cells/kg (dose-level 1) 
and subsequent available dose-levels were 104 CD3+ T-cells/kg (dose-level 2) and 
105 CD3+ T-cells/kg (dose-level 3). In order to implement this adaptive trial design, 
prior patients had to reach D+100 before the subsequent aDLI dose assignment. The 
study design mandated stopping if no acceptable aDLI dose could be identified for a 
patient based on prior patient outcomes. 
Acute and chronic GvHD 
AGVHD was graded according to the Consensus Grading Scale.22 Hyperacute 
GvHD was defined as occurring within 14 days of aDLI. Refractory aGVHD was 
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defined as aGVHD that did not resolve within 3 weeks of treatment with 
corticosteroids. AGVHD treatment was at the discretion of site investigators.  
Patients who were placed onto other randomized studies or given unconventional 
therapy for refractory aGVHD were removed from study at the time of these 
interventions and followed only for survival. Chronic GvHD was diagnosed and 
graded as per contemporaneous NIH criteria.23 
 
Measurement of immune reconstitution  
Immune reconstitution assays were performed on patient PBMC at 1, 2, 3, 4, 6, 9 
and 12 months post-transplant. Patients were eligible for immune reconstitution 
analysis if they had engrafted and had samples available for a minimum of 2 time 
points. Patients were excluded from subsequent immune reconstitution studies from 
time of relapse or administration of experimental or unconventional therapy for 
refractory aGvHD. T-cell subsets, naive and memory, regulatory and effector cell 
phenotypes and antigen-specific T-cell responses were determined by surface and 
intracellular cytokine flow cytometry as previously described.19,20 The frequencies of 
CD4+ Treg and T effectors (Teff) were measured by flow cytometry and defined as 
the percentage of CD4+ T-cells with a CD25hiCD127lo and CD25hiCD127+ phenotype 
respectively. Further details are contained in Supplementary Methods. 
Statistical analysis 
For correlations of phenotypic characteristics of aDLI and residual alloresponses the 
non-parametric test of significance was used. For assessing the significance of 
differences between groups, two-tailed t tests were used throughout. For unpaired t 
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tests, equal variance was not assumed and Welch’s correction was used where 
appropriate. Area-under-the-curve (AUC) was calculated using the trapezoid rule. 
Statistical analysis was performed on Graphpad Prism V4. Overall survival was 





Engraftment and chimerism 
Stem cell infusions contained a median CD34+ cell dose of 9.9 x 106/kg (range 5.2-
17.5) with a median residual CD3+ T-cell dose of 2.0 x 104/kg (range 0-3). Eighteen 
of 19 patients (95%) engrafted (median time to neutrophil engraftment D+12, range 
8-19). Only one of 18 engrafted patients received G-CSF. All patients who engrafted 
achieved full donor chimerism at first testing (median D+28, range D+17-D+40).  The 
patient who failed to engraft had autologous reconstitution. (Table S2).  
 
Characteristics of aDLI 
We analysed the phenotypic and functional characteristics of aDLI prior to infusion. 
Half of the viable infused cells were CD4+ T-cells, with smaller proportions of CD8+ 
T-cells, CD56+ NK cells, CD19+ B cells and CD14+ monocytes.  Infused T-cells were 
predominantly central and effector memory cells (Figure 1 A-B).  A more detailed 
phenotypic characterisation was performed on 7 aDLI products and on 
corresponding unmanipulated donor PBMC.  Consistent phenotypic changes seen in 
alloanergized CD4+ T-cells included increased expression of activation markers 
CD25 and CD69, positive costimulatory receptors CD40L and CD30 and negative 
costimulatory receptors BTLA and CTLA4. Additionally, there was a consistent 
increase in the frequency of CD25+CD127lo CD4+ Treg in accordance with our 
previous observations.20 In contrast, less consistent changes occurred in CD8+ T-
cells, although 5 of 7 products had increased expression of PD1 on CD8+ T-cells 
(Figure 1C). We determined residual alloreactivity in aDLI to quantify the efficiency 
of alloanergization. The median residual alloreactivity was 25% (range 1-65%) for all 
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assessable products. There was no significant difference in residual alloreactivity in 
products generated at different study sites or for different dose levels (Figure S2) or 
using patient or non-patient allostimulators (Figure 1D).  Finally, as aDLI were 
infused fresh before residual alloreactivity results were available, we correlated 
phenotypic characteristics of aDLI with residual alloreactivity to identify real time 
correlates of residual alloreactivity. Levels or changes in expression of individual 
molecules did not correlate closely with residual alloresponses. However, there was 
a significant negative correlation with the ratio of CD4+ Treg to CD4+ Teff in aDLI 
products and residual alloresponses (Figure 1E). 
 
GvHD before and after aDLI 
Incidences of aGvHD pre-aDLI (from the start of conditioning to immediately prior to 
aDLI infusion) and post-aDLI (from aDLI infusion to D+100) are shown in Table 1.  
One of 18 evaluable patients developed aGVHD pre-aDLI (Grade 2, D+22). Three 
patients did not receive aDLI; one died of bacterial sepsis at D+32, one donor was 
unable to donate and one patient failed to engraft. Sixteen patients received aDLI at 
dose-levels 1 (n=4), 2 (n=8), and 3 (n=4), Table S3. No infusional reactions or 
hyperacute GvHD occurred after aDLI. Six patients developed aGVHD of any grade 
post-aDLI at a median D+63 (range D+52-D+98).  One patient (P005) had developed 
and resolved grade 2 aGvHD pre-aDLI, and then presented again after aDLI with 
grade 2 on D+98.  Five additional patients developed aGVHD post-aDLI: 2 patients 
at dose-level 2, (one grade 1 and one grade 4); and 3 patients at dose-level 3 (all 
grade 3). There was a trend to greater residual alloreactivity of aDLI in patients who 
went on to develop aGvHD than those who did not but this did not reach statistical 
significance (median 35% versus 20%, p=0.15, Figure S3). None of the 4 patients 
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receiving aDLI at dose-level 1 and only 2 of the 8 patients who received aDLI at 
dose-level 2 developed Grade 2 or higher aGVHD, compared to 3 of 4 patients who 
received aDLI at dose-level 3. Two patients had refractory aGvHD while the others 
responded to steroids/other systemic immunosuppressive therapies. Four patients 
went on to develop chronic GVHD.  
 
Infections before and after aDLI 
A high proportion of patients (twelve of 19, 63%) had documented bacteremia and 
CMV reactivation occurred in 9 of 17 (53%) at-risk patients during the pre-aDLI 
period. None of these 9 had received CMV prophylaxis, and all developed peripheral 
blood CMV reactivation prior to aDLI at median D+24 (range 16-33 days). Eight at-
risk patients did not develop CMV reactivation pre-aDLI. Five of these received CMV 
prophylaxis as recommended, 2 received prophylaxis after stem cell infusion but not 
during conditioning and one received HSV prophylaxis with famcyclovir and 
valacyclovir. Five patients had BK viruria and five patients had symptomatic viral 
infections in the pre-aDLI period; 3 had oral/nasal HSV infection, one had 
nasopharyngeal RSV infection and one had systemic adenoviral infection.  
 
Only 4/14 at-risk patients (29%) reactivated CMV post-aDLI with an overall 
cumulative incidence of CMV reactivation below 60% at D+180. Of these, 3 were 
receiving immunosuppression for GvHD treatment and 3 successfully cleared CMV 
with antiviral therapy. CMV disease (retinitis) was confirmed in one patient. Four 
patients had EBV reactivation in peripheral blood with no confirmed cases of post-
transplant lymphoproliferative disorder. Two patients were electively treated with 
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rituximab. One had become EBV DNA-negative prior to treatment while the other did 
so on treatment.  Two patients became EBV DNA-negative without any treatment. 
Other viral reactivations/infections occurred in 4 of 4 assessable patients who 
received aDLI at dose-level 1/no aDLI, compared to 4 of 8 patients receiving dose-
level 2 and 3 of 4 patients who received aDLI at dose-level 3. Two patients 
developed aspergillus pneumonia and one patient was positive for aspergillus by 
PCR in broncho-alveolar lavage.  
Immune reconstitution of T-cell subsets  
Sixteen patients were eligible for immune reconstitution studies. Median values and 
ranges for absolute lymphocyte count, CD3+, CD4+ and CD8+ T-cell recovery are 
shown in Figure 2 (A-D). CD4+ T-cells recovered more rapidly than CD8+ T-cells. 
Reconstituting T-cells early post-transplant were predominantly central and effector 
memory cells reflecting the phenotype of infused aDLI, with no emergence of naive 
T-cells until 9-12 months (Figure 2 E-F). 
We next analysed immune reconstitution in relation to the dose of aDLI received.  
Reconstitution of CD4+ and CD8+ T-cell numbers was accelerated in patients 
receiving aDLI at dose-levels 2 and 3 compared to patients receiving dose-level 1/no 
aDLI (Figure 2G-H), although differences in T-cell counts at individual time points 
did not reach statistical significance. In order to better evaluate the impact of aDLI on 
reconstitution of T-cells over the first 4 months post-transplant, we also performed an 
AUC analysis in patients surviving until this point. The D+120 AUC for both CD4+ T-
cell and CD8+ T-cell recovery was significantly greater in patients who received aDLI 
at either dose-level 2 or dose-level 3 compared to those who received dose-level 
1/no aDLI (p=0.04 and 0.02 (CD4+) and p=0.04 and p=0.04 (CD8+) respectively). 
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Additionally, D+120 AUC for both CD4+ and CD8+ T-cell recovery in patients 
receiving aDLI at dose-level 3 was significantly greater than patients receiving aDLI 
at dose-level 2 (p=0.03 and 0.01 respectively). Importantly, there was no significant 
difference in D+120 AUC for either CD4+ or CD8+ T-cell reconstitution in patients 
grouped by age, donor age, TBI or chemotherapy-only conditioning, or higher or 
lower contaminating T-cell doses within the stem cell transplant. Beyond D+120, 
CD4+ T-cell counts in recipients of aDLI at dose-level 3 fell transiently, reaching 
levels similar to those of recipients of aDLI at dose-levels 1 and 2, although a similar 
dip in CD8+ T-cell reconstitution was not observed. This dip in CD4+ T-cell levels 
may have reflected the lympholytic effect of systemic steroid therapy for aGvHD 
initiated in 3 of 4 recipients of aDLI at dose-level 3. 
 
Recovery of virus-specific T-cells 
As virus-specific T-cells identified by multimer technology may lack functionality after 
HSCT,24 we assessed the frequency of functional CMV- and VZV-specific CD4+ and 
CD8+ T-cells by measuring intracellular IFN-γ accumulation after stimulation with 
virus-infected lysates. Thirteen patients who received transplants from CMV and/or 
VZV-seropositive donors were studied.  In several patients, greatly expanded (>50-
fold) frequencies of IFN-γ+ virus-specific T-cells were detectable post-transplant 
compared to levels determined in donor PBMC. None of 3 assessable patients 
receiving Dose 1/no aDLI had detectable functional CMV-specific T-cells in the first 4 
months after transplant despite 3 of 4 having detectable peripheral blood CMV DNA. 
In contrast, 3 of 6 patients receiving aDLI at dose-level 2, and all assessable patients 
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receiving aDLI at dose-level 3 had functional CMV-specific T-cells detectable by this 
time point (Figure 3A-B). 
To assess a broader spectrum of virus-specific T-cell reconstitution, we grouped the 
earliest time points post-transplant, according to dose of aDLI, that functional CMV 
or VZV-specific T-cells were detectable in patient peripheral blood. (Figure 3C-D). 
The median time when virus-specific CD4+ IFN-γ+ T-cells were first detectable was 3 
months and 2.5 months for patients who received aDLI at dose-levels 2 and 3 
respectively, significantly earlier than patients receiving Dose 1/no aDLI (median 9 
months, p=0.03 for comparison with either dose-level 2 or dose-level 3). Similarly, 
functional virus-specific CD8+ T-cells were first detectable at a median of 4 and 3 
months in recipients of aDLI at dose-levels 2 and 3, considerably earlier than in 
patients receiving dose 1/no DaLI (median 9 months) although only dose-level 3 
versus dose-level 1/no aDLI reached statistical significance. 
We also determined the frequency of adenovirus-specific T-cells in P018 who prior to 
aDLI had developed symptomatic adenoviral infection with a high and rising copy 
number of adenovirus by PCR despite systemic antiviral treatment with cidofovir. 
aDLI was followed by marked expansion of donor-derived adenovirus-specific T-cells 
co-incident with a fall and subsequent eradication of adenovirus DNA. (Figure 3E). 
Tumor-associated antigen-specific T-cells 
Donor-derived T-cells specific for the tumor-associated antigen WT1 can provide 
graft-versus-leukemia effects after HSCT.25,26 We therefore measured WT1-specific 
CD4+ and CD8+ IFN-γ+ T-cells in patient peripheral blood. WT1-specific T-cells were 
largely undetectable in peripheral blood from donors. However, large expansions of 
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WT1-specific CD4+ and CD8+ T-cells were detectable in patient peripheral blood 
after HSCT. Furthermore, WT1-specific T-cells were detectable earlier and at higher 
frequencies in patients receiving aDLI at dose-levels 2 and 3 (Figure 3F-G). 
Regulatory T-cell expansion 
We have previously shown that infusion of alloanergized T-cells en bloc with 
haploidentical BM results in an expansion of CD4+ Treg in patient peripheral blood 
post-transplant, and that expanded populations of Treg may contribute to the control 
of alloresponses in this setting.20 We therefore measured the frequencies of CD4+ 
Treg in aDLI pre- and post-alloanergization and in peripheral blood of patients after 
aDLI. CD4+ Treg frequencies were significantly increased in aDLI compared to 
unmanipulated donor PBMC (median 6% versus 3.5%, p=0.004). A further increase 
in the frequencies of CD4+ Treg occurred in patient peripheral blood after infusion of 
aDLI, with a peak frequency occurring at D+120 post-HSCT. Infusion of higher dose-
levels of aDLI was associated with significantly higher frequencies of CD4+ Treg in 
patient peripheral blood at D+60 and D+120 when compared to frequencies in 
patients receiving dose-level 1/no aDLI (Figure 4 A-B).  Expanded populations of 
CD4+CD25hiCD127lo Treg in patient peripheral blood post-transplant expressed high 
levels of FOXP3 consistent with suppressive function (Figure S5). Several patients 
who had demonstrated large expansions of virus-specific T-cells in peripheral blood 
post-transplant (including P016, CMV-specific T-cell expansion and P018, 
adenovirus-specific T-cell expansion) also had large expansions of peripheral blood 
CD4+ Treg. 
However, there was no clear association with relative or absolute numbers of CD4+ 
Treg in patient peripheral blood post-transplant and occurrence of aGvHD. As recent 
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studies have shown that aGvHD is more clearly associated with the ratio of CD4+ 
Treg: Teff than with CD4+ Treg numbers alone after T-cell depleted HSCT,27 we 
calculated the CD4+ Treg: Teff ratio in aDLI pre-infusion, and in patient peripheral 
blood after haploidentical HSCT and aDLI.  Patients who developed Grade 2 or 
higher aGvHD had significantly lower CD4+ Treg: Teff ratios in the peripheral blood 
post-transplant. In addition, the CD4+ Treg: Teff ratio was also significantly lower in 
aDLI products administered to patients who went on to develop aGvHD (Figure 4C). 
Patient Outcomes 
All 16 patients who received HSC and aDLI were evaluable for survival (Table S4). 
Two patients relapsed post-transplant (P010 at D+180, P012 at D+150); both 
subsequently died.  Only one patient (P023) died as a result of viral infection. One 
patient died from aGvHD (P026) after receiving aDLI at dose-level 2. There were 7 
patient deaths from regimen-related toxicity (pulmonary veno-occlusive disease (1 
patient, D+78), respiratory distress syndrome (5 patients, D+59-D313) and 
sepsis/multiorgan failure (1 patient at D+312). An additional patient (P002) died from 
bleeding after a liver biopsy 2 years after transplant. Four of 13 assessable patients 
developed chronic GVHD- limited in one (P027) and extensive in three patients 
(P015, P016, P033). The actuarial overall survival of the 16 patients receiving aDLI 
was 38% at 1 year. Three patients (P005, P015 and P018) are known to be currently 
alive and disease-free with a median follow up of 9 years (range 8.9-9.3). Patient 
004 was alive and disease-free through 5.8 years post-transplant after which she 




We have shown that generation and administration of aDLI after CD34-selected 
myeloablative haploidentical HSCT in patients with acute leukemia and 
myelodysplasia are feasible across multiple clinical sites. While this study highlights 
the potential influence of regimen-related toxicities in high-risk patients on the 
interpretation of early phase studies, we demonstrated that a modest dose of aDLI is 
well tolerated and positively impacts on a range of immune reconstitution 
parameters. 
We observed a relatively low incidence of clinically significant aGvHD at dose-levels 
1 and 2 (2/12 patients) whereas aGvHD occurred in 3 of 4 recipients of aDLI at dose-
level 3 (105 CD3+ T-cells/kg). This should be set within the context of reported 
frequencies of aGVHD after CD34-selected haploidentical HSCT without DLI of 
between 0 and 10% in adults and children.9,28   The maximum tolerated dose of aDLI 
given in the context of this study was therefore 104 T-cell/kg (dose-level 2), lower 
than T-cell doses administered in published reports of CD25-allodepleted DLI and 
our previous studies using alloanergization to reduce alloreactivity of T-cells within 
BM grafts.18,19,29 Several potential explanations are possible. Firstly, in our prior 
studies, 2-3-log greater doses of alloanergized cells were infused at the time of BMT 
which may have optimized homeostatic expansion and the presence and activity of 
relevant immunomodulatory cell populations such as Treg. Secondly, pro-
inflammatory environments have been shown to both reverse anergy in alloreactive 
T cells in vitro and adversely influence the functional stability of potentially 
tolerogenic CD4+ Treg.30,31  In our current study, a notably large proportion of these 
high-risk patients (63% overall and 56% who went on to get aDLI) had proven 
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bacteremia in the first period of the study (pre-aDLI) and all at-risk patients who did 
not receive CMV prophylaxis demonstrated reactivation. This high rate of infectious 
comorbidity could have created a pro-inflammatory, cytokine-rich micro-environment 
impacting adversely on both passive and active tolerance mechanisms in the period 
post-aDLI resulting in an increased frequency of aGvHD.  Finally, alloanergization of 
DLI resulted in less efficient and more variable reduction in residual alloreactivity 
compared to our pre-clinical scale up studies19 or alloanergization of T cell-replete 
donor BM in our previous clinical studies.18,19 This may in turn have contributed to 
breakthrough aGvHD at lower doses of infused T-cells. It is possible that the 
increased variability in the efficiency of alloanergization resulted from either the use 
of non-patient allostimulators or from center effects, although the small numbers in 
this study are insufficient to firmly support or reject these hypotheses. The most 
generalizable means to address the variability would be to implement a real-time 
assay of residual alloreactivity prior to infusion of aDLI. As the ratio of CD4+ 
Treg:Teff in aDLI significantly correlated with residual alloreactivity, use of this 
phenotypic correlate might improve quality control of aDLI whilst facilitating the use 
of fresh cells to preserve optimal viability.  
Infusion of aDLI at a dose above 103 CD3+ T-cells/kg resulted in faster T-cell 
reconstitution than reported after CD34-selected haploidentical HSCT without T-cell 
addback,9,32  and comparable reconstitution to that reported after TCR α/β depletion 
prior to haploidentical HSCT.33 While CD34-selected grafts infused prior to aDLI 
contained up to 3 x 104/kg contaminating CD3+ T-cells, these unmanipulated donor 
T-cells should not have contributed to immune reconstitution as they would likely 




We observed a high incidence of CMV reactivation (53% of at-risk patients) pre-
aDLI, similar to that reported (60% by D+42) in the largest published study of CMV 
reactivation rates in the early post-transplant period after CD34-selected TCD 
haploidentical HSCT.34 Only 29% of at-risk patients on our study had further 
episodes of CMV reactivation after aDLI, with one first reactivation occurring in this 
period so the cumulative incidence of CMV reactivation remained below 60% at 
D+180, in contrast to the study reported by Lilleri et al who found that CMV 
reactivation continued beyond D+40 to reach a cumulative incidence above 80% by 
D+100 post-transplant.34 
Encouragingly, functional virus-specific T-cells became detectable early after aDLI.  
In contrast, virus-specific T-cell responses remained undetectable until 12 months 
after TCD haploidentical HSCT in the absence of additional T-cell infusions in 
previously published studies.35  The median time to reconstitution of detectable CD4+ 
and CD8+ CMV and VZV-specific T-cells in recipients of aDLI at the lowest dose-
level (103 CD3+ T-cells/kg) was 9 months and was significantly earlier in recipients of 
104 CD3+ T-cells/kg (median 3 and 4 months, CD4+ and CD8+ T-cells). This is 
consistent with the provision of a threshold number of viral-specific T-cells contained 
within aDLI that are able to undergo antigen-specific expansion in vivo. Although 
variance in the strategies used for CMV prophylaxis at different clinical centres make 
it impossible to draw firm conclusions regarding the impact of aDLI on CMV 
reactivation and CMV-specific T-cell reconstitution, the rates of CMV reactivation 
after aDLI are comparable to that recently reported with the PTC approach,16 
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suggesting that the emergence of virus-specific T-cells after aDLI might have 
potential to provide functional virus-specific immunity.  
Importantly we also observed expansion of donor-derived tumor–antigen-specific T-
cells which could contribute to Graft-versus-Leukemia (GvL) effects. While our study 
was not designed to assess the impact of aDLI on disease relapse and there were 
confounding effects of early mortality, only 2 of 16 patients who received aDLI 
subsequently relapsed, despite uniformly high-risk disease characteristics. This 
contrasts with some reported outcomes after haploidentical HSCT with PTC, where 
relapse rates of 35-50% have been reported suggesting that this approach may 
result in impairment of donor-derived GvL effects.15,36 However, it is important to 
stress that our study was not designed to determine the clinical efficacy of aDLI in 
terms of provision of functional immunity post-transplant. Thus, while no conclusions 
can be drawn on the impact of aDLI on infections or relapse, the observed results 
support the hypothesis that aDLI may exert beneficial effects on these endpoints and 
provides a rationale for addressing these endpoints in larger subsequent studies. 
Our study also demonstrated a dose-dependent expansion of donor-derived CD4+ 
Treg in the peripheral blood of patients after aDLI, confirming our earlier findings 
after alloanergized BMT. We and others have previously shown that donor CD4+ 
Treg generated by alloanergization play an important role in the control of 
alloresponses mediated by human and murine T-cells.20,37  Observational studies 
have shown higher numbers of CD4+ Treg post-transplant are associated with 
freedom from aGvHD.38 Adoptive therapy with donor-derived CD4+ Tregs has 
recently been shown to reduce the incidence of aGvHD after haploidentical HSCT.39 
Higher ratios of CD4+ Treg:Teff in patients who did not develop aGvHD after aDLI 
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suggest that CD4+ Treg may indeed have a central role in controlling clinically 
significant alloresponses in this setting. While limiting numbers of cells prevented us 
from characterizing the suppressive function of expanded populations of CD4+ 
Tregs, large expansions of CD4+ Treg were seen in several patients who also had 
vigorous expansion of pathogen-specific T-cells demonstrated that expanded CD4+ 
Treg did not result in global immunosuppression. Strategies to potentiate the 
expansion of CD4+ Treg after aDLI may further reduce toxicity and improve the 
therapeutic window of this approach. Additional studies of the suppressive capacity 
and in vivo stability of these Treg would be of interest. 
We are encouraged that only one patient in the study died from aGvHD and only one 
patient from viral infection. However, despite using a chemotherapy-only conditioning 
regimen in the majority of patients, the incidence of non-GvHD treatment-related 
mortality remained disappointingly high. The high rate of infection observed in 
patients during conditioning and immediately thereafter suggests that the baseline 
risk of the study population was high and may have affected study endpoints. With 
the greater acceptance of haploidentical HSCT since the study was conducted, due 
in large part to the successes of the approaches reviewed above, it should become 
increasingly easier to study novel approaches at times when patients are earlier in 
their disease course.  
In summary, we have shown that low doses of aDLI can provide beneficial immune 
reconstitution after CD34-selected myeloablative haploidentical HSCT with 
acceptable rates of aGvHD. As beneficial effects can be observed after aDLI at low 
cell numbers, this may be a valuable strategy to bolster anti-viral and potentially anti-
tumor effects after HSCT undertaken using one of a variety of available approaches 
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to the problem of aGvHD. The approach has the advantage of rapid in vivo 
expansion of donor CD4+ Treg which may provide an additional mechanism to 
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Table 1 acute GvHD pre-and post-aDLI   
Patient  aDLI  
dose level 
and day 
Pre-aDLI  Post-aDLI  
Acute GvHD 
Time, Grade (stage) 
001 Level 1,
 
 D+35 None None 
002 Level 1,
 
 D+35 None None 
003 Level 1,
 
 D+35 None None 
004 Level 1,
  
D+42 None None 
005 Level 2, D+42 D+22 Grade 2 (S2,GI 1, L0) D+98 Grade 2 (S3,GI 0, L1) 
010 Level 2, D+34 None None 
012 Level 2, D+35 None None 
013 None given† None N/E 
025 None given§ None N/E 
026 Level 2, D+35 None D+52 Grade 4 (S0,GI 4, L4) 
027 Level 2, D+42 None None 
028 | | None Given N/E N/E 
030 Level 2, D+42 None None 
033 Level 2, D+35 None D+54 Grade 1 (S2,GI 0, L0) 
035 Level 2, D+35 None None 
015 Level 3, D+36 None D+63 Grade 3 (S3,GI 3, L0) 
016 Level 3, D+35 None D+62 Grade 3 (S2,GI 3, L0) 
018 Level 3, D+35 None None 
023 Level 3, D+35 None D+89 Grade 3 (S0,GI 1, L3) 
 
Level 1, 103 CD3 T-cells/Kg, Level 2 104 CD3 T-cells/kg, Level 3, 105 CD3 T-cells/kg; S, skin; GI, 
gastrointestinal; L, liver 
†
 




    Table 2 Infections pre- and post-aDLI   





Pre-aDLI  Post-aDLI 











 D+35 -/- None None None None VZV skin D+76 None None 
002 Level 1,
 
 D+35 +/- Stomatococcua blood 
D+1 
BK urine D-8 None None EBV blood D+147,BK urine 






 D+35 -/+ E.Coli blood D-3 
VRE blood D0 
HSV oral D+28 
CMV blood D+33 
HSV D+28 None None None None 
004 Level 1,
  
D+42 +/+ Enterobact. blood D-6 
Proteus Urine D+32 
BK urine D+5, CMV 
blood D+26, RSV 
NP D+26 
RSV D+26 None EBV blood D+234 None None 
005 Level 2, D+42 +/+ None None None None RSV NP D+209 RSV D+209 None 
010 Level 2, D+34 +/+ Staph Epi blood D-8 CMV blood D+20,30 None None CMV blood D+74,84,96, HHV6 BM D+78 None None 
012 Level 2, D+35 -/+ C.Diff colitis D-2 CMV blood D+20 None None None None None 
013 None given† -/+ Stomatococcus + VRE 
blood D+11 
N/E                    N/E                  N/E                     N/E                    N/E                     N/E                     
025 None given§ +/+ Corynebacterium 
blood D+27 
HSV nasal D+24                    
CMV blood D+27                              
HSV nasal 
D+24                               
 N/E                      N/E                     N/E                      
026 Level 2, D+35 -/+ None None None None None None None 
027 Level 2, D+42 +/+ None CMV blood D+16 None Aspergillus 
BAL D+13 
CMV blood ends D+73 then reactivates 
D+209  
CMV retinitis 
D+114 to D+176 
None 
028 | | None Given +/+ Fusobact + α-haem 
strep blood D+11 
N/E                 N/E                 N/E                    N/E                      N/E                     N/E                      
030 Level 2, D+42 -/+ Staph Epi blood D-1 HSV oral D+35 HSV oral None None None None 
033 Level 2, D+35 +/+ None BK urine D+13 
 
None None BK blood D+53, EBV blood D+137. CMV 
blood D+179 
None None 
035 Level 2, D+35 +/+ VRE blood D+3 CMV blood D+23 None None None None Presumed fungal 
pneumonia D+62 
015 Level 3, D+36 +/- α-haem strep blood 
D+1, C.Diff colitis D+8 
None None None EBV blood D+124 EBV D+124  None 
016 Level 3, D+35 +/+ α-haem strep blood 
D+1 
BK urine D+13, 
CMV blood D+27 
None None CMV blood D+106,  cleared after D+141 None Aspergillus 
pneumonia D+172 
018 Level 3, D+35 -/- None Adeno blood, urine, 
stool D+18 BK urine 
D+25 
Adenov. None Adenovirus  
(cleared by D+73) 
None None 
023 Level 3, D+35 +/+ VRE Blood D+5 CMV blood D+24 None None BK blood D+76, Adenovirus urine, stool, 
sputum D+106 




 CD3 T-cells/Kg, Level 2 10
4
 CD3 T-cells/kg, Level 3, 10
5
 CD3 T-cells/kg; D, donor; R, recipient; BKV, BK virus, VRE, vancomycin-resistant enterococcus; HSV, herpes simplex 
virus; RSV, respiratory syncytial virus;  CMV, cytomegalovirus;  C Diff, clostridium difficile; BAL; Bronch-alveolar lavage, †
 
died D+32 of bacterial sepsis prior to infusion of aDLI. § Donor not 
able to donate. | | non-engraftment followed by autologous reconstitutiion
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Figure 1 Phenotypic and functional characteristics of alloanergized donor 
lymphocyte infusions 
(A)  Cellular composition of alloanergized donor lymphocyte infusions (aDLI) prior to 
infusion. Values shown are mean (+/- sd) percentages of viable cells for aDLI 
generated for 9 different patients. 
(B) Proportions of CD4+ and CD8+ T-cells in aDLI with CD45RA+CD62L+ naive, 
CD45RA-CD62L+ central memory (CM), CD45RA-CD62L- effector memory (EM) and 
CD45RA+CD62L- T effector memory-RA (TEMRA) phenotypes. Mean percentages of 
viable CD4+ or CD8+ T-cells are shown for aDLI generated for 9 different patients. 
(C) Phenotypic heat map of viable CD4+ and CD8+ cells in aDLI compared to 
expression levels in unmanipulated donor PBMC. Expression patterns are shown for 
aDLI for 7 different patients. Treg frequencies were determined in 10 aDLI products; 
data is shown for the 7 products where full phenotypic analysis was available.  ICOS, 
inducible T-cell costimulator; PD1, programmed death 1; BTLA, B and T lymphocyte 
attenuator; CTLA4, cytotoxic T lymphocyte antigen 4; Treg, CD25+CD127lo 
regulatory T-cell.  
(D) Residual alloproliferative responses of aDLI after ex vivo alloanergization. Lines 
and adjacent numbers are medians. Results are shown for aDLI products generated 
for 14 patients. 
(E) Correlation between CD4+ Treg:Teffector ratio and residual alloresponses in 
aDLI.  R2 value is for Spearman correlation coefficient and p value is for two-tailed t 
test.  Dashed line represents 95% confidence limits. Results are shown for aDLI 





Figure 2 Reconstitution of immune cell subsets after T-cell depleted 
haploidentical HSCT and infusion of aDLI 
(A)-(D) Absolute numbers of lymphocytes (A), CD3+ (B), CD4+ (C) and CD8+ T-cells 
(D) in patient peripheral blood after T-cell depleted haploidentical HSCT and infusion 
of aDLI.  Medians and interquartile ranges are shown for 16 patients eligible for 
immune reconstitution studies. 
(E)-(F)  Absolute numbers of CD4+ (E) and CD8+ (F) T-cells in patient peripheral 
blood after T-cell depleted haploidentical HSCT and infusion of aDLI with naive, 
central memory (CM), effector memory (EM) and T effector memory-RA (TEMRA) 
phenotypes. Medians are shown for 16 patients eligible for immune reconstitution 
studies. 
(G)-(H) Absolute numbers of CD4+ (G) and CD8+ T-cells (H) in patient peripheral 
blood after T-cell depleted haploidentical HSCT and infusion of aDLI.  Median values 
are shown for 16 patients eligible for immune reconstitution studies grouped 




Figure 3 Reconstitution of virus- and tumor antigen-specific T-cells after T-cell 
depleted haploidentical HSCT and aDLI 
(A)-(B) Frequencies of CMV-specific IFN-γ+ CD4+ (A) and CD8+ (B) T-cells in donor 
and patient peripheral blood after T-cell depleted haploidentical HSCT and infusion 
of aDLI. Individual results are shown for patients who received transplants from 
CMV-seropositive donors and were eligible for immune reconstitution studies and 
one patient who received a transplant from a CMV-seronegative donor (P02030). 
Patients are colour coded according to the dose of aDLI. ND= not detectable.  
(D-E) First time points when virus-specific IFN-γ+ T-cells were detectable in 
peripheral blood of individual patients after transplant.  Crosses denote CMV-specific 
T-cells and circles denote VZV-specific T-cells. Results are shown for 13 patients 
with CMV- and/or VZV-seropositive donors who were eligible for immune 
reconstitution studies.  Values are grouped and colour coded according to the dose 
of aDLI. Horizontal lines are medians. 
(F-G) Frequencies of WT1-specific IFN-γ+ CD4+ (A) and CD8+ (B) T-cells in donor 
and patient peripheral blood after T-cell depleted haploidentical HSCT and infusion 
of aDLI. Individual results are shown for 14 patients eligible for immune 
reconstitution studies, colour coded according to the infused dose of viable donor 





Figure 4 Reconstitution of CD4+ regulatory T-cells (Treg) after T-cell depleted 
haploidentical HSCT and aDLI 
 (A) CD4+ Treg in donor and patient peripheral blood after T-cell depleted 
haploidentical HSCT and infusion of aDLI. Representative dot plots are shown for 
patients who received aDLI at a dose of 103 CD3+ T-cells/kg (P004) and aDLI at a 
dose of 105 CD3+ T-cells/kg (P018). Boxed regions contain CD25+CD127lo Tregs and 
numbers denote the frequencies of Treg expressed as a percentage of CD4+ T-cells. 
(B) Frequencies of CD4+ Treg in DLI before and after alloanergization, and patient 
peripheral blood after T-cell depleted haploidentical HSCT and infusion of aDLI.  
Values are shown for 14 patients eligible for immune reconstitution studies grouped 
according to dose of aDLI.  Horizontal lines are medians. Treg frequencies at D+120 
in two patients who also had large expansions of peripheral blood virus-specific T-
cells post-transplant (P016, CMV-specific T-cell expansion) and P018, adenovirus-
specific T-cell expansion) are highlighted. 
(C) Ratio of frequencies of CD4+ Treg;Teffector cells in aDLI, and in patient 
peripheral blood after T-cell depleted haploidentical HSCT and infusion of aDLI.  
Values are shown for 13 patients eligible for immune reconstitution studies grouped 
according to whether they did or did not develop acute GvHD (grades 2-4). 
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